+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a



Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a



Glycobiology 22(3): 352-360



It is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution (1)H-(13)C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036323714

Download citation: RISBibTeXText

PMID: 21921061

DOI: 10.1093/glycob/cwr139


Related references

Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. Journal of Neuroscience 25(7): 1620-1628, 2005

Chemoenzymatic synthesis of biotin-appended analogues of gangliosides GM2, GM1, GD1a and GalNAc-GD1a for solid-phase applications and improved ELISA tests. Organic and Biomolecular Chemistry 9(16): 5809-5815, 2011

Complex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies. Plos one 10(4): E0124004, 2015

High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: Reexamination of GD1a immunolocalization. Journal of Neurochemistry 75(1): 404-412, 2000

Clinical correlates of anti-GD1a antibodies. Neuropathology & Applied Neurobiology 21(Suppl. 1): 36-37, 1995

Recurrent GBS with GD1a anti-ganglioside antibodies. Journal of the Peripheral Nervous System 17(1): 135-137, 2012

Acute ophthalmoparesis associated with anti-GM1, anti-GD1a, and anti-GD1b antibodies after enterovirus infection in a 6-year-old girl. Journal of Child Neurology 22(4): 432-434, 2007

Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies. Journal of Neurology 251(1): 24-29, 2004

Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Annals of Neurology 39(4): 539-543, 1996

Amyotrophic lateral sclerosis associated with IgG anti-GalNAc-GD1a antibodies. Clinical Neurology and Neurosurgery 110(7): 722-724, 2008

Guillain-Barré syndrome with antibodies to GD1a/GD1b complex. Journal of Neurology Neurosurgery and Psychiatry 78(5): 548-549, 2007

IgG anti-Galnac-GD1a antibodies bind to neuromuscular junctions of rat hemidiaphragm. Muscle and Nerve 46(5): 705-710, 2012

Structural requirements of anti-GD1a antibodies determine their target specificity. Brain 131(Pt 7): 1926-1939, 2008

Recurrent multiple cranial nerve palsy and anti-GD1a antibodies. Muscle and Nerve 43(3): 447-448, 2011

Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle and Nerve 25(6): 828-836, 2002